She had read enough to know the word. She arrived at her appointment with hypoactive sexual desire disorder written on a folded piece of paper in her pocket, having practiced saying it in the car. She got as far as describing the problem. Her doctor nodded kindly and said that this was very common at her age, that stress and sleep were probably playing a part, and that things often settle down. The appointment moved on. The piece of paper stayed in her pocket.

She was not dismissed rudely. That is what makes this pattern so hard to name. She was dismissed warmly, by someone who meant well, and who did not know that a global consensus statement with the strongest available evidence rating exists on exactly this subject.

Here is what makes the silence around this topic more than an awkwardness problem: there is an established, internationally endorsed treatment pathway, and the gap between the evidence and the exam room is enormous.

In 2019, an international task force convened by the International Menopause Society published the Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Lead authors included Professor Susan R Davis, Rodney Baber, and Nicholas Panay. It was endorsed by eleven international medical societies, among them the Endocrine Society and the International Society for the Study of Women’s Sexual Health. It was published simultaneously across four journals.

Its finding on hypoactive sexual desire disorder in women in menopause, meaning persistently low desire that causes personal distress, was rated Level I, Grade A. In evidence classification, that is the ceiling.

What the statement actually concluded, in plain terms

Testosterone therapy at doses that approximate normal premenopausal levels improves sexual desire, arousal, orgasmic function, pleasure, and sexual responsiveness, and reduces sexual distress, beyond the effect of placebo.

Three qualifications matter, and any honest account of this includes them. The recommendation applies to women in menopause; evidence in women in late reproductive age, before the transition, is more limited, though the International Society for the Study of Women’s Sexual Health supports its consideration there. It applies to formulations producing physiological, not supraphysiological, levels, which specifically excludes injectables, pellets, and compounded preparations. And long term safety data has not been established, which is a real limitation rather than a formality.

None of those qualifications explain why the conversation is not happening at all. They explain how it should be conducted once it starts.

The size of the gap

Hypoactive sexual desire disorder affects roughly 10% of adult women, and it does not distribute evenly across life. It peaks in midlife. Data from the PRESIDE study found it affects 12.3% of women aged 45 to 64, compared with 8.9% of women aged 18 to 44 and 7.4% of women over 65.

Read that peak alongside a separate finding. In a clinic-based study across twenty US sites, among women who met the diagnostic criteria for the condition, only 53% had ever sought care from a health professional for it.

So the condition peaks in exactly the years when women are seeing clinicians more often, not less. And roughly half of the women who have it have never raised it in the room.

This is what a care gap looks like when it is nobody’s fault in particular. The woman does not raise it because she has absorbed that it is not a medical topic. The clinician does not raise it because there are eleven minutes and three other things on the list. The evidence sits in four journals, endorsed by eleven societies, unread by either of them.

What closing it actually requires

It requires the woman to arrive with specific language, because the conversation will usually not start on its own.

Not “my libido is low,” which invites reassurance. Instead: the desire change is persistent, it causes me personal distress, and I would like to know whether it meets criteria for hypoactive sexual desire disorder and what my options are. Those three components, persistence, distress, and a named condition, are what move a conversation from sympathy toward assessment.

Go back to the woman with the folded paper in her pocket. On her second attempt, months later, she read it out loud rather than describing the problem in her own words. The appointment went entirely differently. Not because her doctor had become a different person, but because the sentence she used contained a diagnosis, a criterion, and a request.

The paper was always the right paper. She just had to take it out of her pocket.

Here is the landing. There is an internationally endorsed, highest-grade evidence base for treating this condition, and the largest obstacle between most women and that conversation is that nobody in the room starts it.

The action is to write your sentence before you go. Three parts: how long the change has persisted, whether it causes you distress, and the explicit request to discuss whether it meets criteria for hypoactive sexual desire disorder. Bring it written down if saying it feels hard. Reading it aloud counts.

That is what the free assessment at EmpressHealth.ai is built to produce: not a diagnosis, but a structured account of your own pattern, in the language a clinician can act on in the eleven minutes available.

The evidence already exists. What is missing is the sentence that gets you to it.